

BREAST DISEASES

Jay R. Harris
Samuel Hellman
I. Craig Henderson
David W. Kinne



SECOND EDITION

J. B. LIPPINCOTT COMPANY

TION

BREAST DISEASES

EDITED BY

.....

Jay R. Harris, M.D.

Professor of Radiation Therapy
Harvard Medical School
Clinical and Educational Director
Joint Center for Radiation Therapy
Boston, Massachusetts

Samuel Hellman, M.D.

Dean and Vice President
Division of Biological Sciences
Pritzker School of Medicine
University of Chicago
Chicago, Illinois

I. Craig Henderson, M.D.

Associate Professor of Medicine
Harvard Medical School
Medical Coordinator
Breast Evaluation Center
Division of Clinical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

David W. Kinne, M.D.

Chief, Breast Service
Memorial Sloan-Kettering Cancer Center
New York, New York

69 CONTRIBUTORS

J. B. LIPPINCOTT COMPANY

Philadelphia New York London Hagerstown



Developmental Editor: *Julia Richardson*
Project Editor: *Tom Gibbons*
Indexer: *Julia Figures*
Designer: *Doug Smock*
Production Manager: *Helen Ewan*
Production Coordinator: *Antoinette Bauer*
Compositor: *Circle Graphics*
Printer/Binder: *Halliday*
Color Insert: *Princeton Polychrome*

2nd Edition

Copyright © 1991, by J. B. Lippincott Company. Copyright © 1987, by J. B. Lippincott Company. All rights reserved. No part of this book may be used or reproduced in any manner whatsoever without written permission except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write J. B. Lippincott Company, East Washington Square, Philadelphia, Pennsylvania 19105.

6 5 4 3 2 1

Library of Congress Cataloging-in-Publication Data

Breast diseases / edited by Jay R. Harris . . . [et al.] ; 69 contributors.—2nd ed.
p. cm.
Includes bibliographical references.
Includes index.
ISBN 0-397-51079-9
1. Breast—Diseases. 2. Breast—Cancer. I. Harris, Jay R.
[DNLM: 1. Breast Diseases. 2. Breast Neoplasms. WP 840 B8283]
RG491.B742 1991
618.1'9—dc20
DLC
for Library of Congress

90-15633
CIP

The authors and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

CONTRIBUTORS

Leslie Bernstein, Ph.D.

Associate Professor, Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California

Marluce Bibbo, M.D., Sc.D., FIAC

Professor and Director, Section of Cytopathology, The University of Chicago; Director, Cytopathology Laboratory, University of Chicago Hospitals, Chicago, Illinois

Bruce A. Bornstein, M.D.

Instructor of Radiation Therapy, Harvard Medical School; Staff Radiation Oncologist, Joint Center for Radiation Therapy; Clinical Associate, Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Mary Ellen Bowles, M.S.

New York, New York

John Boyages, M.B., B.S. (Hons), FRACR

Part-Time Clinical Lecturer, University of Sydney; Staff Specialist in Radiation Oncology, Westmead Hospital, Westmead, New South Wales, Australia

James B. Breitmeyer, M.D., Ph.D.

Instructor in Medicine, Harvard Medical School; Clinician, Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Ted Chaglassian, M.D., FACS

Assistant Professor of Clinical Surgery, Cornell University Medical College; Assistant Clinical Member, Memorial Sloan-Kettering Cancer Center; Associate Attending Surgeon, Memorial Hospital for Cancer and Allied Diseases; Associate Attending Surgeon, Chief, Plastic and Reconstructive Surgical Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Grace H. Christ, M.A., C.S.W.

Director, Department of Social Work, Memorial Sloan-Kettering Cancer Center, New York, New York

C. Norman Coleman, M.D.

Professor and Chairman, Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts

Steven E. Come, M.D.

Associate Professor of Medicine, Harvard Medical School; Director, Hematology/Oncology Units, Beth Israel Hospital; Attending Physician, Dana-Farber Cancer Institute, Boston, Massachusetts

James L. Connolly, M.D.

Associate Professor of Pathology, Harvard Medical School; Pathologist, Beth Israel Hospital; Consultant, Dana-Farber Cancer Institute, Boston, Massachusetts

D. David Dershaw, M.D.

Associate Professor of Clinical Radiology, Cornell University College of Medicine; Associate Attending, Department of Medical Imaging, Memorial Sloan-Kettering Cancer Center, New York, New York

Karen M. Hassey Dow, R.N., M.S.

Nurse Specialist, Beth Israel Hospital, Boston, Massachusetts

Timothy J. Eberlein, M.D.

Associate Professor of Surgery, Harvard Medical School; Chief, Division of Surgical Oncology, Brigham and Women's Hospital, Boston, Massachusetts

Kathleen M. Foley, M.D.

Professor of Neurology and Pharmacology, Cornell University Medical College; Chief, Pain Service; Attending Neurologist, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York

Judy E. Garber, M.D., M.P.H.

Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts

Rebecca S. Gelman

Associate Professor of Biostatistics and Radiotherapy, Harvard Medical School and School of Public Health; Associate Scientist, Dana-Farber Cancer Institute, Boston, Massachusetts

J. Peter Glass, M.D.

Associate Professor of Neurology, University of Florida College of Medicine, University Medical Center, Jacksonville, Florida

Lawrence J. Gottlieb, M.D., FACS

Assistant Professor, Department of Surgery, Pritzker School of Medicine; Chairman, Section of Plastic and Reconstructive Surgery, University of Chicago Hospitals and Clinics, Chicago, Illinois

Thomas B. Hakes, M.D.

Associate Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, New York

Jay R. Harris, M.D.

Professor, Harvard Medical School; Clinical and Educational Director, Joint Center for Radiation Therapy, Boston, Massachusetts

Daniel F. Hayes, M.D.

Assistant Professor in Medicine, Harvard Medical School, The Breast Evaluation Center and the Laboratory of Clinical Pharmacology, Dana-Farber Cancer Institute, Boston, Massachusetts

John H. Healey, M.D.

Assistant Attending Surgeon, Department of Orthopaedic Surgery; Assistant Professor of Surgery (Orthopaedics), Cornell University Medical College, Memorial Sloan-Kettering Cancer Center, New York, New York

Samuel Hellman, M.D.

Dean and A.N. Pritzker Professor, The Division of the Biological Sciences and the Pritzker School of Medicine; Vice President for the Medical Center, University of Chicago, Chicago, Illinois

Brian E. Henderson, M.D.

Professor, Department of Preventive Medicine, University of Southern California School of Medicine; Medical Director, Kenneth Norris Jr. Cancer Hospital, Los Angeles, California

I. Craig Henderson, M.D.

Associate Professor of Medicine, Harvard Medical School; Medical Coordinator, Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Philip C. Hoffman, M.D.

Associate Professor of Medicine, Section of Hematology/Oncology, The University of Chicago, The University of Chicago Hospitals, Chicago, Illinois

Jimmie C. Holland, M.D.

Professor of Psychiatry, Cornell University Medical College; Chief, Psychiatry Service, Memorial Sloan-Kettering Cancer Center, New York, New York

V. Craig Jordan, Ph.D., D.Sc.

Professor of Human Oncology and Pharmacology; Director, Breast Cancer Program, University of Wisconsin, Clinical Cancer Center, Madison, Wisconsin

William D. Kaplan, M.D.

Associate Professor of Radiology, Harvard Medical School; Chief, Oncologist Nuclear Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts

David W. Kinne, M.D.

Associate Professor of Surgery, Cornell University Medical College; Attending Surgeon, Chief, Breast Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Rosalyn Kleban, M.S.W., C.S.W.

Administrative Supervisor, Department of Social Work, Memorial Sloan-Kettering Cancer Center, New York, New York

Daniel B. Kopans, M.D., FACP

Associate Professor of Radiology, Harvard Medical School; Director of Breast Imaging, Massachusetts General Hospital; Assistant Director of Ambulatory Radiology, Boston, Massachusetts

Thomas J. Krizek, M.D.

Professor and Chairman, Department of Surgery, University of Chicago, The Pritzker School of Medicine; Professor and Chairman, Department of Surgery, The University of Chicago Hospitals, Chicago, Illinois

Stephanie J. London, M.D., Dr.Ph.

Assistant Professor, Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California

Susan M. Love, M.D.

Clinical Assistant Professor in Surgery, Harvard Medical School; Director, Faulkner Breast Center; Surgical Oncologist, Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Patricia M. McCormack, M.D., FACS

Associate Professor of Surgery, Cornell University School of Medicine; Associate Attending Surgeon, Thoracic Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Beryl McCormick, M.D.

Associate Professor of Radiation Oncology in Medicine, Cornell University Medical College; Associate Attending Radiation Oncologist, Memorial Sloan-Kettering Cancer Center, New York, New York

Susan A. McKenney, R.N., C, M.S.N., O.C.N.

Nursing Coordinator, Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Anthony B. Miller, M.B., FRCP

Professor, Department of Preventive Medicine and Biostatistics, University of Toronto, Toronto, Ontario, Canada

Michael P. Moore, M.D., Ph.D.

Assistant Professor of Surgery, Cornell University Medical College, Memorial Sloan-Kettering Cancer Center, New York, New York

Briggs W. Morrison, M.D.

Clinical Fellow, Harvard Medical School; Fellow in Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Monica Morrow, M.D.

Associate Professor of Surgery, University of Chicago; Attending Surgeon, University of Chicago Hospitals, Chicago, Illinois

Donna S. Neuberg, Sc.D.

Lecturer in Biostatistics, Harvard School of Public Health; Lecturer, Dana-Farber Cancer Institute, Boston, Massachusetts

C. Kent Osborne, M.D.

Professor of Medicine, Head, Section of Clinical Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio; Attending Physician, Medical Center Hospital, San Antonio, Texas

Michael P. Osborne, M.D., M.S., FRCS, FACS

Associate Professor of Surgery, Cornell University Medical College; Associate Member and Head, Breast Cancer Research Laboratory; Associate Attending Surgeon, Memorial Sloan-Kettering Cancer Center, New York, New York

Robert T. Osteen, M.D.

Associate Professor of Surgery, Harvard Medical School; Co-Director of Surgical Oncology Division, Brigham and Women's Hospital, Boston, Massachusetts

Leroy M. Parker, M.D.

Assistant Professor of Medicine, Harvard Medical School; Assistant Physician in Medicine, Dana-Farber Cancer Institute; Associate Physician, Brigham & Women's Hospital, Boston, Massachusetts; Chief of Medical Oncology, Norwood Hospital, Norwood, Massachusetts; Chief of Medical Oncology, Southwood Community Hospital, Norfolk, Massachusetts

Lissa Parsonnet, M.S., A.C.S.W.

Administrative Supervisor, Department of Social Work, Memorial Sloan-Kettering Cancer Center, New York, New York

Pravin-Kumar K. Patel, M.D., M.Sc.

Research Fellow, University of Chicago, Department of Surgery, Section of Plastic and Reconstructive Surgery, University of Chicago Hospitals and Clinics, Chicago, Illinois

Jeanne A. Petrek, M.D., FACS

Assistant Professor of Surgery, Cornell University Medical College; Adjunct Faculty Member, The Rockefeller University; Assistant Attending Surgeon, Memorial Sloan-Kettering Cancer Center, New York, New York

Abram Recht, M.D.

Assistant Professor, Joint Center for Radiation Therapy, Harvard Medical School; Radiation Therapist, Beth Israel Hospital; Assistant Physician, Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Massachusetts

Paul Peter Rosen, M.D.

Professor of Pathology, Cornell University Medical College; Attending Pathologist and Member, Memorial Sloan-Kettering Cancer Center, New York, New York

Julia H. Rowland, Ph.D.

Department of Psychiatry, Georgetown University Hospital, Washington, D.C.

Norman L. Sadowsky, M.D.

Professor of Radiology (Clinical), Tufts University School of Medicine; Instructor of Andrology, Harvard Medical School; Chief of Radiology, Faulkner Hospital; Director of Faulkner-Sagoff Centre for Breast Health Care, Boston, Massachusetts

Lowell E. Schnipper, M.D.

Theodore W. and Evelyn G. Berenson Associate Professor of Medicine, Harvard Medical School; Associate Chairman, Department of Medicine, Chief, Oncology Division, Beth Israel Hospital, Boston, Massachusetts

Stuart J. Schnitt, M.D.

Assistant Professor of Pathology, Harvard Medical School; Associate Pathologist, Beth Israel Hospital; Consultant in Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts

Lisa M. Sclafani, M.D.

Instructor, Cornell University Medical College, Department of Surgery; Assistant Attending Surgeon, Breast Service, Memorial Sloan-Kettering Cancer Center, New York, New York

Charles L. Shapiro, M.D.

Clinical Fellow in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts

Barbara L. Smith, M.D., Ph.D.

Instructor in Surgery, Harvard Medical School; Associate Surgeon, Brigham and Women's Hospital, Boston, Massachusetts

Helene S. Smith, M.D.

Director, Geraldine Brush Cancer Research Institute, Pacific Presbyterian Medical Center, San Francisco, California

Mark J. Stillman, M.D.

Assistant Clinical Professor, University of Washington Medical School; Co-Medical Director, Hospice of Seattle; Providence Medical Center and Swedish Medical Center, Seattle, Washington

David J. Sugarbaker, M.D.

Assistant Professor of Surgery, Harvard Medical School; Chief, Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts

Maureen E. Trudeau, M.D., FRCP(C)

Assistant Professor of Medicine, University of Toronto; Medical Oncologist, Women's College Hospital, Toronto, Ontario, Canada

Shelly Underbill, M.D.

Associate Pathologist, West Allis Memorial Hospital, West Allis, Wisconsin

Raymond P. Warrell, Jr., M.D.

Associate Professor of Medicine, Cornell University Medical College; Associate Member, Memorial Sloan-Kettering Cancer Center, New York, New York

Ralph R. Weichselbaum, M.D.

Harold H. Hines, Jr., Professor; Professor and Chairman, University of Chicago, Pritzker School of Medicine; Professor and Chairman, University of Chicago Hospitals, Chicago, Illinois

Walter Willett, M.D., Dr.P.H.

Professor of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts

Joachim Yabalom, M.D.

Assistant Professor, Cornell University Medical College; Assistant Attending Radiation Oncologist, Memorial Sloan-Kettering Cancer Center, New York, New York

PREFACE

The management of patients with breast diseases, particularly those who are at risk for or who have developed breast cancer, continues to be a major public health problem—one that demands the involvement and expertise of physicians and scientists in a wide variety of disciplines. It was with this fact in mind that we compiled the first edition of *Breast Diseases*. Our intention was to cover the range of issues subsumed under this heading by assembling experts in the field to provide the important material in a comprehensive, balanced, and easy-to-read work. In reviewing the history of the field, we were struck by the succession of theories that were strongly held despite a paucity of supporting data. We wished, in contrast, to provide the reader with the pertinent information in order to allow for independent review and analysis. The guiding principles behind the first edition, then, were to provide information that was current, to emphasize data regarding breast diseases that are scientifically valid, and to avoid dogma. We have been gratified by the success of the first edition and have taken this to mean that, at least in part, we achieved our goals.

The second edition of *Breast Diseases* was prompted both by the rapid pace of research in breast cancer and by our desire to provide the most current information to the reader. In this edition, we have attempted to maintain the same guiding principles as in the first edition. We have added new sections and expanded old sections in response to new developments. A number of new spe-

cialists have been added to the list of contributors. In particular, this edition provides new information on the diagnosis and management of benign breast conditions, the evaluation and management of mammographic abnormalities, the management of in situ cancers, the influence of exogenous hormone administration on the risk of developing breast cancer and the risk of recurrence following treatment, new treatment modalities, and advances in molecular biology and other laboratory sciences that are likely to shed light on the topic of breast cancer. In addition, we have added a new feature—a Management Summary—at the end of each clinically related section. The purpose of these summaries is to provide a succinctly worded conclusion regarding the clinical guidelines that we believe can be derived from the currently available information. The summaries are the responsibility of the editors, and it is our hope that they will make the detailed information that is provided more accessible, particularly for the non-specialist.

We hope that this second edition of *Breast Diseases* will be of use both to the wide range of physicians who are concerned with diseases of the breast and to their patients.

Jay R. Harris, M.D.
Samuel Hellman, M.D.
I. Craig Henderson, M.D.
David W. Kinne, M.D.

CONTENTS

1 *BREAST DEVELOPMENT AND ANATOMY, 1*
Michael P. Osborne

2 *BENIGN BREAST DISORDERS, 15*

PATHOLOGY OF BENIGN BREAST DISORDERS, 15
Stuart J. Schnitt and James L. Connolly

BENIGN PAPILLARY LESIONS OF THE BREAST, 31
Lisa M. Sclafani

FIBROADENOMAS, 34
Barbara L. Smith

DUCT ECTASIA, PERIDUCTAL MASTITIS, AND BREAST INFECTIONS, 38
Barbara L. Smith

BREAST TRAUMA, HEMATOMA, AND FAT NECROSIS, 43
Monica Morrow

GYNECOMASTIA, 46
Timothy J. Eberlein

3 *AESTHETIC SURGERY FOR THE NONDISEASED
BREAST, 51*
Thomas J. Krizek

4 *MANAGEMENT OF COMMON BREAST DISORDERS, 63*

BREAST PAIN, 63
Monica Morrow

NIPPLE DISCHARGE, 73
Monica Morrow

MASS: LUMP/CYST, 77
Michael P. Moore

ABNORMAL MAMMOGRAM, 79
David W. Kinne

.....
5 *PHYSICAL EXAMINATION AND MAMMOGRAPHY IN THE
DIAGNOSIS OF BREAST DISEASE,* 81

David W. Kinne and Daniel B. Kopans

.....
6 *BIOPSY OF A PALPABLE LESION,* 107

David W. Kinne

.....
7 *NEEDLE LOCALIZATION,* 113

David W. Kinne, D. David Dershaw and Paul Peter Rosen

.....
8 *CAUSES OF BREAST CANCER AND HIGH-RISK
GROUPS,* 119

INCIDENCE AND DEMOGRAPHICS: RADIATION RISK, 119

Anthony B. Miller

**THE ROLE OF ENDOGENOUS AND EXOGENOUS HORMONES IN THE ETIOLOGY OF
BREAST CANCER,** 126

Brian E. Henderson and Leslie Bernstein

DIETARY FACTORS AND THE ETIOLOGY OF BREAST CANCER, 136

Walter Willett and Stephanie J. London

FAMILIAL ASPECTS OF BREAST CANCER, 142

Judy E. Garber

MANAGEMENT OF HIGH-RISK GROUPS, 153

Judy E. Garber, I. Craig Henderson, Susan M. Love and Rebecca S. Gelman

.....
9 *BIOLOGY,* 165

NATURAL HISTORY OF BREAST CANCER, 165

Jay R. Harris and Samuel Hellman

IN VITRO MODELS IN HUMAN BREAST CANCER, 181

Helene S. Smith

ANIMAL MODELS OF HORMONE-DEPENDENT BREAST CANCER, 189

V. Craig Jordan

ONCOGENES AND BREAST CANCER, 197

Briggs W. Morrison

IMMUNOLOGIC ASPECTS OF BREAST CANCER TUMOR BIOLOGY, 206

James B. Breitmeyer

.....
10 *EARLY DETECTION OF BREAST CANCER,* 215

Anthony B. Miller

-
- 11** *IN SITU CARCINOMA, 229*
PATHOLOGY OF IN SITU CARCINOMA, 229
Stuart J. Schnitt
CLINICAL MANAGEMENT OF DUCTAL CARCINOMA IN SITU, 233
Jay R. Harris
CLINICAL MANAGEMENT OF LOBULAR CARCINOMA IN SITU, 239
David W. Kinne
-
- 12** *THE PATHOLOGY OF INVASIVE BREAST CARCINOMA, 245*
Paul Peter Rosen
-
- 13** *CYTOLOGY OF FINE-NEEDLE ASPIRATION, 297*
Marluce Bibbo and Shelly Underhill
-
- 14** *RECEPTORS, 301*
C. Kent Osborne
-
- 15** *STAGING AND PROGNOSTIC FACTORS, 327*
STAGING OF BREAST CARCINOMA, 327
Jay R. Harris
PROGNOSTIC FACTORS, 332
I. Craig Henderson
-
- 16** *PRIMARY TREATMENT OF BREAST CANCER, 347*
SURGERY, 347
David W. Kinne
POSTMASTECTOMY RADIOTHERAPY, 373
Jay R. Harris
CONSERVATIVE SURGERY AND RADIOTHERAPY, 388
Jay R. Harris and Abram Recht
CONCLUDING REMARKS, 420
Samuel Hellman
-
- 17** *ADJUVANT SYSTEMIC THERAPY OF EARLY BREAST CANCER, 427*
I. Craig Henderson
-
- 18** *BREAST RECONSTRUCTION AFTER MASTECTOMY, 487*
Thomas J. Krizek

19 *EVALUATION OF PATIENTS FOLLOWING PRIMARY THERAPY, 505*

Daniel F. Hayes and William D. Kaplan

20 *LOCAL RECURRENCE FOLLOWING MASTECTOMY, 527*

Abram Recht and Daniel F. Hayes

21 *LOCAL RECURRENCE FOLLOWING BREAST CONSERVATION, 541*

Abram Recht, Timothy J. Eberlein and Norman L. Sadowsky

22 *PRINCIPLES IN THE MANAGEMENT OF METASTATIC DISEASE, 547*

INTEGRATION OF LOCAL AND SYSTEMIC THERAPIES, 547

I. Craig Henderson and Jay R. Harris

ENDOCRINE THERAPY OF METASTATIC BREAST CANCER, 559

I. Craig Henderson

CHEMOTHERAPY FOR METASTATIC DISEASE, 604

I. Craig Henderson

NEW FORMS OF SYSTEMIC THERAPY, INCLUDING IMMUNOTHERAPY, 665

Timothy J. Eberlein, I. Craig Henderson and James B. Breitmeyer

INNOVATIVE APPROACHES TO LOCAL THERAPY, 673

Bruce A. Bornstein and C. Norman Coleman

23 *SPECIFIC SITES OF METASTATIC DISEASE AND EMERGENCIES, 679*

BRAIN METASTASES IN PATIENTS WITH BREAST CANCER, 679

J. Peter Glass and Kathleen M. Foley

BREAST CANCER AND EPIDURAL SPINAL CORD COMPRESSION: DIAGNOSIS AND THERAPY, 688

Mark J. Stillman and Kathleen M. Foley

CARCINOMATOUS MENINGITIS, 700

J. Peter Glass and Kathleen M. Foley

OCULAR METASTASES FROM BREAST CANCER, 710

Beryl McCormick

MANAGEMENT OF PATHOLOGIC FRACTURES, 713

John H. Healey

BRACHIAL PLEXOPATHY IN PATIENTS WITH BREAST CANCER, 722

Kathleen M. Foley

LYMPHANGITIC SPREAD OF CARCINOMA OF THE BREAST, 730

Maureen E. Trudeau

MALIGNANT EFFUSIONS IN BREAST CANCER, 735

Charles L. Shapiro and David J. Sugarbaker

GASTROINTESTINAL AND HEPATIC METASTASES, 745*Philip C. Hoffman***HYPERCALCEMIA AND OSTEOLYSIS IN BREAST CANCER, 750***Raymond P. Warrell, Jr.***MYELOPHTHISIC ANEMIA AND OTHER ASPECTS OF BONE MARROW INVOLVEMENT, 761***Steven E. Come and Lowell E. Schnipper***24 SPECIAL THERAPEUTIC PROBLEMS, 767****LOCALLY ADVANCED BREAST CANCER, 767***Monica Morrow, Philip C. Hoffman and Ralph R. Weichselbaum***INFLAMMATORY CARCINOMA OF THE BREAST, 775***Leroy M. Parker, John Boyages and Timothy J. Eberlein***MALE BREAST CANCER, 782***David W. Kinne and Thomas B. Hakes***CYSTOSARCOMA PHYLLODES, 791***Jeanne A. Petrek***PAGET DISEASE OF THE NIPPLE, 797***Robert T. Osteen***OTHER CANCERS IN THE BREAST, 804***Jeanne A. Petrek***BREAST CANCER AND PREGNANCY, 809***Jeanne A. Petrek***OCCULT PRIMARY TUMOR WITH AXILLARY METASTASES, 817***Michael P. Moore and Joachim Yabalom***LYMPHEDEMA FOLLOWING AXILLARY SURGERY:
ELEPHANTIASIS CHIRURGICA, 820***Lawrence J. Gottlieb and Pravin-Kumar K. Patel***MANAGEMENT OF THE CONTRALATERAL BREAST, 827***David W. Kinne***POST-TREATMENT SARCOMAS, 834***Jeanne A. Petrek***RECONSTRUCTION FOLLOWING NECROSIS OR LOCAL RECURRENCE, 840***Ted Chaglassian and Patricia M. McCormack***25 PATIENT REHABILITATION AND SUPPORT, 849****PSYCHOLOGICAL REACTIONS TO BREAST CANCER AND ITS TREATMENT, 849***Julia H. Rowland and Jimmie C. Holland***EDUCATIONAL AND SUPPORT PROGRAMS FOR BREAST CANCER PATIENTS AND THEIR FAMILIES, 866***Grace H. Christ, Mary Ellen Bowles, Rosalyn Kleban and Lissa Parsonnet***PATIENT REHABILITATION AND SUPPORT: NURSING, 872***Susan A. McKenney and Karen M. Hassey Dow*

.....
26 *INTERPRETING CLINICAL DATA,* 883
Rebecca S. Gelman and Donna S. Neuberg

INDEX, 907

The color illustrations are to be found between pages 80 and 81.

occur at any point along the milk streak from the axilla to the groin. Rarely, accessory true mammary glands develop. These are most often located in the axilla (polymastia). During pregnancy and lactation, an accessory breast may swell; occasionally, if there is an associated nipple, it may function.

Hypoplasia is the underdevelopment of the breast, congenital absence of a breast is termed *amastia*. When breast tissue is lacking but a nipple is present, the condition is termed *amazia*. A wide range of breast abnormalities have been described and may be classified as follows:^{5,6}

- Unilateral hypoplasia, contralateral normal
- Bilateral hypoplasia with asymmetry
- Unilateral hyperplasia, contralateral normal
- Bilateral hyperplasia with asymmetry
- Unilateral hypoplasia, contralateral hyperplasia
- Unilateral hypoplasia of breast, thorax, and pectoral muscles (Poland's syndrome)

Most of these abnormalities are not severe. The severest deformity, amastia or marked breast hypoplasia, is associated with hypoplasia of the pectoral muscle in 90% of cases,⁷ but the reverse does not apply. Ninety-two percent of women with pectoral muscle abnormalities have a normal breast.⁸ Congenital abnormalities of the pectoral muscle are usually manifested by the lack of the lower third of the muscle and an associated deformity of the ipsilateral rib cage. The association between absence of the pectoral muscle, chest wall deformity, and breast abnormalities was first recognized by Poland in 1841. The original description, however, did not note the concomitant abnormalities of the hand (synbrachydactyly, with hypoplasia of the middle phalanges and central skin webbing),⁹ and considerable controversy has evolved concerning the validity of the eponym for this congenital syndrome.^{10,11}

Acquired Abnormalities

The most common—and avoidable—cause of amazia is iatrogenic. Injudicious biopsy of a precociously developing breast results in excision of most of the breast bud and subsequent marked deformity during puberty. The use of radiation therapy in prepubertal females to treat either hemangioma of the breast or intrathoracic disease may also result in amazia. Traumatic injury of the developing breast, such as that resulting from a severe cutaneous burn, with subsequent contracture, may also result in deformity.

NORMAL BREAST DEVELOPMENT DURING PUBERTY

Puberty in girls begins at the age of 10 to 12 years as a result of the influence of hypothalamic gonadotropin-releasing hormones secreted into the hypothalamic–pituitary portal venous system. The basophilic cells of the anterior pituitary release follicle-stimulating hormone (FSH) and luteinizing

hormone (LH). Follicle-stimulating hormone causes the primordial ovarian follicles to mature into graafian follicles, which secrete estrogens, primarily in the form of 17 β -estradiol. These hormones induce the growth and maturation of the breasts and genital organs.¹² During the first 1 to 2 years after menarche, there is unbalanced hypothalamic–adenohypophyseal function because the maturation of the primordial ovarian follicles does not result in ovulation or a luteal phase. Therefore, ovarian estrogen synthesis predominates over luteal progesterone synthesis. The physiologic effect of estrogens on the maturing breast is to stimulate longitudinal ductal growth of ductal epithelium. Terminal ductules also form buds that precede further breast lobules. Simultaneously, periductal connective tissues increase in volume and elasticity, with enhanced vascularity and fat deposition. These initial changes are induced by estrogens synthesized in immature ovarian follicles, which are anovulatory; subsequently, mature follicles ovulate and the corpus luteum releases progesterone. The relative role of these hormones is not clear. In experimental studies, estrogens alone induce a pronounced ductular increase, whereas progesterone alone does not. The two hormones together produce full ductular–lobular–alveolar development of mammary tissues.¹² There is marked individual variation in development of the breast, making it impossible to categorize histologic changes on the basis of age.^{3,4} Breast development by age has been described by external morphologic changes. The evolution of the breast from childhood to maturity has been divided into five phases by Tanner,¹³ as shown in Table 1-1.

MORPHOLOGY

The Adult Breast

The adult breast lies between the second and sixth ribs in the vertical axis, and between the sternal edge and the midaxillary line in the horizontal axis (Fig. 1-1). The average

Table 1-1
Phases of Breast Development

Phase I (age: puberty): Preadolescent elevation of the nipple with no palpable glandular tissue or areolar pigmentation.
Phase II (age: 11.1 \pm 1.1 yr): Presence of glandular tissue in the subareolar region. The nipple and breast project as a single mound from the chest wall.
Phase III (age: 12.2 \pm 1.09 yr): Increase in the amount of readily palpable glandular tissue with enlargement of the breast and increased diameter and pigmentation of the areola. The contour of the breast and nipple remains in a single plane.
Phase IV (age: 13.1 \pm 1.15 yr): Enlargement of the areola and increased areola pigmentation. The nipple and areola form a secondary mound above the level of the breast.
Phase V (age: 15.3 \pm 1.7 yr): Final adolescent development of a smooth contour with no projection of the areola and nipple.




FIGURE 1-1. Normal anatomy of the breast and pectoralis major muscle.

1. Perforating branches from internal mammary artery and vein
2. Pectoral branches from thoracoacromial artery and vein
3. External mammary branch from lateral thoracic artery and vein
4. Branches from subscapular and thoracodorsal arteries and veins
5. Lateral branches of third, fourth, and fifth intercostal arteries and veins
6. Internal mammary artery and veins
7. Sternocostal head of pectoralis major muscle
8. Clavicular head of pectoralis major muscle
9. Axillary artery and vein
10. Cephalic vein
11. Axillary sheath
12. Latissimus dorsi muscle
13. Serratus anterior muscle
14. External abdominal oblique muscle

breast measures 10 to 12 cm in diameter and its average thickness centrally is 5 to 7 cm. Breast tissue also projects into the axilla as the axillary tail of Spence. The contour of the breast varies but is usually domelike, with a conical configuration in the nulliparous woman and pendulous in the parous woman. The breast comprises three major structures: skin, subcutaneous tissue, and breast tissue, with the last comprising both parenchyma and stroma. The parenchyma is divided into 15 to 20 segments that converge at the nipple in a radial arrangement. The collecting ducts draining each segment are 2 mm in diameter with subareolar lactiferous sinuses 5 to 8 mm in diameter. Between 5 and 10 major collecting milk ducts open at the nipple.

The nomenclature of the duct system is varied. The branching system may be named in a logical fashion, starting with the collecting ducts in the nipple and extending to the ducts draining each alveolus, as shown in Table 1-2.

Each duct drains a lobe made up of 20 to 40 lobules. Each lobule consists of 10 to 100 alveoli or tubulosaccular secretory units. The microanatomy has been described in detail by Parks.¹⁴ The stroma and subcutaneous tissues of the breast contain fat, connective tissue, blood vessels, nerves, and lymphatics.

The skin of the breast is thin and contains hair follicles, sebaceous glands, and eccrine sweat glands. The nipple, which is located over the fourth intercostal space in the nonpendulous breast, contains abundant sensory nerve endings, including Ruffini-like bodies and end-bulbs of Krause. Also, there are sebaceous and apocrine sweat glands, but no hair follicles. The areola is circular and pigmented, measuring 15 to 60 mm in diameter. Morgagni's tubercles, located near the periphery of the areola, are elevations formed by the openings of the ducts of Montgomery's glands. Montgomery's glands are large, sebaceous glands capable of secreting milk; they represent an intermediate stage between sweat and mammary glands. Fascial tissues envelop the breast. The superficial pectoral fascia envelops the breast and is continuous with the superficial abdominal fascia of Camper. The undersurface of the breast lies on the deep pectoral fascia, covering the pectoralis major and anterior serratus muscles. Connecting these two fascial layers are fibrous bands (Cooper's suspensory ligaments) that represent the "natural" means of support of the breast.

Table 1-2
Nomenclature of the Breast Epithelial System

Major ducts	{ Collecting ducts Lactiferous sinuses Segmental ducts Subsegmental ducts
Terminal duct-lobular unit (TDLU)	{ Terminal ducts Extralobular Intralobular Lobules Alveoli

Blood Supply of the Breast

The principal blood supply to the breast is derived from the internal mammary and lateral thoracic arteries. Approximately 60% of the breast, mainly the medial and central parts, is supplied by the anterior perforating branches of the internal mammary artery. About 30% of the breast, mainly the upper, outer quadrant, is supplied by the lateral thoracic artery. The pectoral branch of the thoracoacromial artery: the lateral branches of the third, fourth, and fifth intercostal arteries; and the subscapular and thoracodorsal arteries all make minor contributions to the blood supply.

Lymphatic Drainage of the Breast

Lymph Vessels

The subepithelial or papillary plexus of the lymphatics of the breast are confluent with the subepithelial lymphatics over the surface of the body. These valveless lymphatic vessels communicate with subdermal lymphatic vessels and merge with Sappey's subareolar plexus. The subareolar plexus receives lymphatic vessels from the nipple and areola and communicates by way of vertical lymphatic vessels that are equivalent to those connecting the subepithelial and subdermal plexus elsewhere.¹⁵ Lymph flows unidirectionally from the superficial to deep plexus and from the subareolar plexus through the lymphatic vessels of the lactiferous duct to the perilobular and deep subcutaneous plexus. The periductal lymphatic vessels lie just outside the myoepithelial layer of the duct wall.¹⁶

Flow from the deep subcutaneous and intramammary lymphatic vessels moves centrifugally toward the axillary and internal mammary lymph nodes. Injection studies with radiolabeled colloid¹⁷ have demonstrated the physiology of lymph flow and have countered the old hypothesis of centripetal flow toward Sappey's subareolar plexus. It has been estimated that about 3% of the lymph from the breast flows to the internal mammary chain, whereas 97% flows to the axillary nodes.¹⁸ Drainage of lymph to the internal mammary chain may be observed following injection of any quadrant of the breast.

Axillary Lymph Nodes

The topographical anatomy of the axillary lymph nodes has been studied as the major route of regional spread in primary mammary carcinoma. The anatomic arrangement of the axillary lymph nodes has been subject to many different classifications. The most detailed studies are those of Pickren, which show the pathologic anatomy of tumor spread.¹⁹ Axillary lymph nodes may be grouped as the apical or subclavicular nodes, lying medial to the pectoralis minor muscle, and the axillary vein lymph nodes, grouped along the axillary vein from the pectoralis minor muscle to the lateral limit of the axilla; the interpectoral (Rotter's) nodes, lying between the pectoralis major and minor muscles along the lateral pectoral nerve; the scapular group, comprising